Publications Database

Dove D. et al. (2012)

Medications for adolescents and young adults with autism spectrum disorders: A systematic review.

Pediatrics

130(4), pp. 717 -726.

Read Abstract (New Window)

Doyle C. A. , McDougle C. J. (2012)

Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.

Dialogues in Clinical Neuroscience

14(3), pp. 263-279.

Read Abstract (New Window) Read Full (New Window)

Figgitt D. P. , McClellan K. J. (2000)

Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders

Drugs

60(4), pp. 925-954

Read Abstract (New Window)

Harvey R. J. , Cooray S. E. (1995)

The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female

International Clinical Psychopharmacology

10(3), pp. 201-203

Read Abstract (New Window)

Kolevzon A. , Mathewson K. , Hollander E. (2006)

Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.

Journal of Clinical Psychiatry

67(3), pp. 407-414

Read Abstract (New Window)

Martin A. et al. (2003)

Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.

Journal of Autism and Developmental Disorders

33(1), pp. 77-85

Read Abstract (New Window)

Masi G. (2004)

Pharmacotherapy of pervasive developmental disorders in children and adolescents.

CNS Drugs

18(14), pp. 1031-1052

Read Abstract (New Window)

McDougle C. J. , Kresch L. E. , Posey D. J. (2000)

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

Journal of Autism and Developmental Disorders

30(5), pp. 427-435

Read Abstract (New Window)

Mohiuddin S. , Ghaziuddin M. (2013)

Psychopharmacology of autism spectrum disorders: A selective review.

Autism

17(6), pp. 645-654.

Read Abstract (New Window)

Moore M. L. , Eichner S. F. , Jones J. R. (2004)

Treating functional impairment of autism with selective serotonin-reuptake inhibitors.

Annals of Pharmacotherapy

38(9), pp. 1515-1519

Read Abstract (New Window)

American Society of Health-System Pharmacists (2008)

Fluvoxamine.

Bethesda, MD: American Society of Health-System Pharmacists

Read Full (New Window)

Scahill L. , Koenig K. (1999)

Pharmacotherapy in children and adolescents with pervasive developmental disorders.

Journal of Child and Adolescent Psychiatric Nursing

12(1), pp. 41-43

Read Abstract (New Window)

Soorya L. , Hollander E. , Kiarashi J. (2008)

Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 753-771

Read Abstract (New Window)

Sugie Y. et al. (2005)

Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.

Journal of Autism and Developmental Disorders

35(3), pp. 377-385

Read Abstract (New Window)

Vasa R. A. et al. (2014)

A systematic review of treatments for anxiety in youth with autism spectrum disorders.

Journal of Autism and Developmental Disorders

December, 44(12), pp. 3215-3229.

Read Abstract (New Window)

Williams K. J. et al. (2011)

Cochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Evidence-Based Child Health: A Cochrane Review Journal

6(4), pp. 1044-1078

Read Abstract (New Window)

Williams K. J. et al. (2013)

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Cochrane Database of Systematic Reviews

CD004677

Read Abstract (New Window) Read Full (New Window)

Yano H. , Matsumoto H. (2011)

A case of pervasive developmental disorder complicated by social anxiety disorder responding well to fluvoxamine therapy.

Tokai Journal of Experimental and Clinical Medicine

36(2), pp. 44-46

Read Abstract (New Window) Read Full (New Window)